News | Mammography | June 14, 2019

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

Eighteen-month, 48-state campaign looks to improve access to breast health education and mammography screening services

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

June 14, 2019 — Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused on improving access to breast health education and mammography screening services for every woman that needs it, especially those most reluctant. At the center of the campaign, Fujifilm will be traveling around the U.S. with its ‘Aspire to Be Fearless’ mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

Fujifilm kicked-off the campaign by supporting an educational event, the Pink Table Brunch, on June 12, 2019 in Portland, Ore. The event featured experts in the field of health, nutrition and breast care. Each presenter shared the latest information about what participants need to know in order to help lessen the fear if they or a loved one is diagnosed with breast cancer. Nisha Jackson, Ph.D., author of a new book entitled “Brilliant Burnout,” signed her latest book at the event.

According to Fujifilm, breast cancer is one of the most feared cancers among women and some women may feel so apprehensive that they put off their breast exams.1 National Cancer Institute statistics show 1 in 8 women may be diagnosed with breast cancer at some time during her life2. Finding breast cancer early and getting state-of-the-art cancer treatment are the most important strategies to prevent deaths from breast cancer.3  Women whose breast cancer is detected at an early stage have on average a 90 percent survival rate in the first five years.4 Unfortunately, minority women are more likely to be diagnosed at a later stage of breast cancer, in part due to barriers to timely screening mammography, resulting in poorer mortality and survival outcomes.5

The ‘Aspire to Be Fearless’ mobile mammography coach will be equipped with a waiting room, dressing room, Aspire Cristalle digital mammography system with digital breast tomosynthesis and Aspire Bellus II mammography diagnostic workstation. Mammography screening services will be available beginning fall 2019. A series of educational events will be hosted by Fujifilm throughout the year in select markets around the country, reaching 48 states over the course of 18 months.

For more information please visit www.fujimed.com

 

References

1.  “Overcoming the Fear of Breast Cancer.” HealthyWomen.Org. Retrieved from https://www.healthywomen.org/content/article/overcoming-fear-breast-cancer

2. “Breast Cancer Risk in American Women.” National Cancer Institute. Retrieved from https://www.cancer.gov/types/breast/risk-fact-sheet

3. “American Cancer Society Recommendations for the Early Detection of Breast Cancer.” American Cancer Society. Retrieved from https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

4. “Survival Rates for Breast Cancer.”  American Cancer Society.” Retrieved from https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html

5. “Gendered and Racialized Social Expectations, Barriers, and Delayed Breast Cancer Diagnosis” Cancer Journal (September 24, 2018).  Retrieved from https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.31636?purchase_referrer=www.breastcancer.org&tracking_action=preview_click&r3_referer=wol&show_checkout=1

Related Content

Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Category A

Category A

Feature | Breast Density | April 03, 2020 | By Dayna Williams M.D., Shivani Chaudhry, M.D., and Laurie R. Margolies, M.D.
Breast cancer is the most common cance
Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Feature | Radiation Dose Management | April 02, 2020 | By Melinda Taschetta-Millane
Rising concerns over...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Mammography | March 25, 2020
March 25, 2020 — The...
The 2020 Society of Breast Imaging/American College of Radiology (SBI/ACR) annual symposium has been cancelled, and the event rescheduled for April 8-11, 2020, in Savannah, Ga. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SBI20
News | Society of Breast Imaging (SBI) | March 16, 2020
March 16, 2020 — The 2020 Society of Breast Imaging/American College of Radiology (...
DBT, sometimes called 3-D mammography, emerged in the last decade as a powerful tool for breast cancer screening

Images in a 57-year-old woman noted to have "good prognosis" invasive cancer detected at digital breast tomosynthesis (DBT) screening. (a) Craniocaudal view of the left breast obtained with the two-dimensional digital mammography (DM) portion of the DM/DBT screening study demonstrates a subtle area of distortion in the medial left breast. (b) Single-slice image from the left craniocaudal DBT portion of the screening study shows an area of bridging distortion (circle). (c) Electronically enlarged image of the area of concern seen on the left craniocaudal view in a single DBT slice as shown in b. (d) Targeted US scan demonstrates two small adjacent irregular solid masses. US-guided core biopsy yielded an invasive carcinoma of the tubular subtype that was estrogen receptor positive, progesterone receptor positive, and human epidermal growth factor receptor 2 negative. The results of the sentinel node biopsy were negative. Image courtesy of the Radiological Society of North America

News | Breast Imaging | March 11, 2020
March 11, 2020 — A new study published in the journal ...
SoftVue image stacks of sound speed, as shown for cases ranging across the four Breast Imaging Reporting and Data System (BI-RADS) breast density categories

Example: SoftVue image stacks of sound speed, as shown for cases ranging across the four Breast Imaging Reporting and Data System (BI-RADS) breast density categories ((a), fatty; (b), scattered; (c), heterogeneously dense; (d), extremely dense). Note the quantitative scale indicating that absolute measurements are obtained. Image courtesy of MDPI

News | Breast Imaging | March 10, 2020
March 10, 2020 — ...
The study concludes that a combination of Artificial Intelligence algorithms and the interpretations of radiologists could, in the U.S. alone, result in a half million women not having to undergo unnecessary diagnostic tests every year

Researchers who participated in the DM (digital mammography) DREAM Challenge.

News | Mammography | March 07, 2020
March 7, 2020 — The stu...
Christopher Comstock, M.D., ECOG-ACRIN Cancer Research Group study published in JAMA builds evidence for use of abbreviated MRI in women with dense breasts

Christopher Comstock, M.D., (Memorial Sloan Kettering Cancer Center) is the lead author of a paper in JAMA that reports that abbreviated breast MRI detected significantly more (almost 2 and a half times as many) breast cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breasts. Photo courtesy of Memorial Sloan Kettering Cancer Center

News | Breast Imaging | February 26, 2020
February 26, 2020 — According to a study
Women 75-plus May Not Benefit from Breast Cancer Screening
News | Mammography | February 25, 2020
February 25, 2020 — According to newly published research in an article titled...